## Antje M Richter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6889429/publications.pdf

Version: 2024-02-01

567281 752698 20 654 15 20 citations h-index g-index papers 20 20 20 981 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 114-128.	7.4	197
2	Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Molecular Cancer, 2010, 9, 264.	19.2	50
3	Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics, 2009, 4, 571-576.	2.7	48
4	RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi. Journal of Investigative Dermatology, 2012, 132, 687-694.	0.7	42
5	Impact of Natural Compounds on DNA Methylation Levels of the Tumor Suppressor Gene RASSF1A in Cancer. International Journal of Molecular Sciences, 2017, 18, 2160.	4.1	36
6	The tumor suppressor RASSF1A induces the YAP1 target gene <i>ANKRD1</i> that is epigenetically inactivated in human cancers and inhibits tumor growth. Oncotarget, 2017, 8, 88437-88452.	1.8	32
7	Epigenetic Silencing of Erythropoietin in Human Cancers. Genes and Cancer, 2011, 2, 65-73.	1.9	31
8	Aberrant Promoter Methylation of the Tumour Suppressor RASSF10 and Its Growth Inhibitory Function in Breast Cancer. Cancers, 2016, 8, 26.	3.7	25
9	The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms. Genes and Cancer, 2014, 5, 365-374.	1.9	25
10	ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Scientific Reports, 2014, 4, 6899.	3.3	24
11	Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi. Cancers, 2015, 7, 1233-1243.	3.7	20
12	Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma. Cancers, 2013, 5, 1566-1576.	3.7	19
13	The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms. BMC Cancer, 2016, 16, 49.	2.6	19
14	Promoter Methylation Status of Ras-Association Domain Family Member in Pheochromocytoma. Frontiers in Endocrinology, 2015, 6, 21.	3.5	17
15	ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. Clinical Epigenetics, 2017, 9, 60.	4.1	15
16	Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function. Clinical Epigenetics, 2019, 11, 182.	4.1	15
17	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. Cancers, 2020, 12, 3528.	3.7	13
18	RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene, 2020, 39, 3114-3127.	5.9	12

## ANTJE M RICHTER

#	Article	lF	CITATION
19	RASSF10 Is a TGF $\hat{i}^2$ -Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer. Cancers, 2019, 11, 1976.	3.7	8
20	The ZAR1 protein in cancer; from epigenetic silencing to functional characterisation and epigenetic therapy of tumour suppressors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188417.	7.4	6